Xencor reports positive interim Phase 1 results for XmAb942; half-life >71 days

Xencor Inc

XmAb942 well tolerated; no serious AEs, no discontinuations.
Half-life >71 days supports 12-week maintenance dosing in planned Phase 2b UC study.
Phase 2b XENITH-UC trial in moderate-to-severely active UC expected to start H2 2025 (n~220).
TL1A x IL23p19 bispecific lead selection on track; FIH study planned for 2026.
Company to host call at 5pm ET today.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.